Novel sulfamoyl benzamides as selective CB(2) agonists with improved in vitro metabolic stability.

Bioorg Med Chem Lett 2010 Jan 17;20(1):387-91. Epub 2009 Oct 17.

Department of Chemistry, Adolor Corporation, 700 Pennsylvania Drive, Exton, PA 19341, USA.

A lead optimization campaign in our previously reported sulfamoyl benzamide class of CB(2) agonists was conducted to improve the in vitro metabolic stability profile in this series while retaining high potency and selectivity for the CB(2) receptor. From this study, compound 14, N-(3,4-dimethyl-5-(morpholinosulfonyl)phenyl)-2,2-dimethylbutanamide, was identified as a potent and selective CB(2) agonist exhibiting moderate in vitro metabolic stability and oral bioavailability. Compound 14 demonstrated in vivo efficacy in a rat model of post-surgical pain.

Download full-text PDF

Source
http://linkinghub.elsevier.com/retrieve/pii/S0960894X0901473
Publisher Site
http://dx.doi.org/10.1016/j.bmcl.2009.10.062DOI Listing
January 2010
40 Reads

Publication Analysis

Top Keywords

metabolic stability
12
vitro metabolic
12
selective cb2
8
cb2 agonists
8
bioavailability compound
4
series retaining
4
retaining high
4
oral bioavailability
4
high potency
4
profile series
4
compound demonstrated
4
improve vitro
4
conducted improve
4
agonists conducted
4
stability profile
4
potency selectivity
4
demonstrated vivo
4
selectivity cb2
4
exhibiting moderate
4
compound n-34-dimethyl-5-morpholinosulfonylphenyl-22-dimethylbutanamide
4

Similar Publications